Salivary β2-Microglobulin Analysis in Chronic Kidney Disease and Hemodialyzed Patients

Background: β2-Microglobulin (β2m) is a major component in dialysis-related amyloidosis, a disabling disease affecting long-term dialysis patients. Methods: β2m and other components were analyzed in saliva and serum from 53 individuals in 4 subgroups: healthy normal controls, diabetes mellitus (DM), chronic kidney disease (CKD) and hemodialysis (HD) patients. Results: Median salivary and mean serum β2m concentrations were 78% higher in both saliva (p = 0.048) and serum (p = 0.047) in DM patients; 118% (p = 0.016) and 907% (p = 0.007) higher, respectively, in CKD patients, and 328% (p = 0.0001) and 2,710% (p = 0.001) higher, respectively, in HD patients, compared with healthy controls. The correlation analysis between salivary and serum β2m concentrations showed a low correlation rate in HD patients (r = –0.18), but was rather high in CKD patients (r = 0.50). Conclusions: Salivary analysis of β2m is a reliable method for evaluating serum β2m levels in CKD patients, and may help predict the potential for development of CKD-induced amyloidosis.

[1]  H. Grey,et al.  Beta2 microglobulin and lymphocytic infiltration in Sjögren's syndrome. , 1975, The New England journal of medicine.

[2]  H. Grey,et al.  Elevated salivary and synovial fluid beta2-microglobulin in Sjogren's syndrome and rheumatoid arthritis. , 1975, Science.

[3]  L. Björck,et al.  beta 2-Microglobulin in saliva and its relation to flow rate in different glands in man. , 1982, Archives of oral biology.

[4]  N. Taniguchi,et al.  beta 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. , 1993, The Journal of clinical investigation.

[5]  A. Davison.  beta 2-microglobulin and amyloidosis: who is at risk? , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  H. Ukeda,et al.  Spectrophotometric assay for superoxide dismutase based on tetrazolium salt 3'--1--(phenylamino)-carbonyl--3, 4-tetrazolium]-bis(4-methoxy-6-nitro)benzenesulfonic acid hydrate reduction by xanthine-xanthine oxidase. , 1997, Analytical biochemistry.

[7]  Roger Detels,et al.  Oral Fluids as an Alternative to Serum for Measurement of Markers of Immune Activation , 1998, Clinical Diagnostic Laboratory Immunology.

[8]  G. Littarru,et al.  Antioxidant status and dialysis: plasma and saliva antioxidant activity in patients with fluctuating urate levels. , 1998, Free radical research.

[9]  P. Ureña,et al.  Circulating biochemical markers of bone remodeling in uremic patients. , 1999, Kidney international.

[10]  C. Kao,et al.  Decreased salivary function in patients with end-stage renal disease requiring hemodialysis. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[11]  T. Drüeke.  β2‐Microglobulin and amyloidosis , 2000 .

[12]  C. Pankhurst,et al.  Sialochemical markers of salivary gland involvement with Sjögren's syndrome secondary to rheumatoid arthritis and primary biliary cirrhosis. , 2000, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[13]  J. Chanard,et al.  Filtration of native and glycated beta2-microglobulin by charged and neutral dialysis membranes. , 2001, Kidney international.

[14]  R. Vanholder,et al.  Uremic toxins and peritoneal dialysis. , 2001, Kidney international. Supplement.

[15]  R. Nagler,et al.  New insights into salivary lactate dehydrogenase of human subjects. , 2001, The Journal of laboratory and clinical medicine.

[16]  Jürgen Floege,et al.  β2-Microglobulin–derived amyloidosis: An update , 2001 .

[17]  J. Floege,et al.  beta2-microglobulin-derived amyloidosis: an update. , 2001, Kidney international. Supplement.

[18]  R. Nagler,et al.  Characterization of the differentiated antioxidant profile of human saliva. , 2002, Free radical biology & medicine.

[19]  T. Çermik,et al.  Salivary function in patients with chronic renal failure undergoing hemodialysis , 2002, Annals of nuclear medicine.

[20]  R. Nagler,et al.  Saliva Analysis in the Clinical Setting: Revisiting an Underused Diagnostic Tool , 2002, Journal of Investigative Medicine.

[21]  J. Sabio,et al.  Salivary and serum beta2-microglobulin and gamma-glutamyl-transferase in patients with primary Sjögren syndrome and Sjögren syndrome secondary to systemic lupus erythematosus. , 2003, Clinica chimica acta; international journal of clinical chemistry.

[22]  C. Zoccali,et al.  Salivary and lacrimal secretion is reduced in patients with ESRD. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[23]  A. Hermetter,et al.  Effect of hemodialysis on the antioxidative properties of serum. , 2003, Biochimica et biophysica acta.

[24]  R. Michelis,et al.  Carbonyl stress induced by intravenous iron during haemodialysis. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[25]  R. Michelis,et al.  Intravenous iron-gluconate during haemodialysis modifies plasma beta2-microglobulin properties and levels. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.